SCHEMBL3018686

SCHEMBL3018686

Cc1cc(C)cc(Cc2csc(N3CCN(S(=O)(=O)c4c(F)c(Br)cc(F)c4Br)CC3)n2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.36
ALDH1A1 P00352 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAPK1 P28482 2/20 0.34
MAPT P10636 4/20 0.34
USP2 O75604 1/20 0.34
RECQL P46063 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
LMNA P02545 2/20 0.33
HTR6 P50406 1/20 0.33
DNM1L O00429 3/20 0.32
PKM P14618 2/20 0.32
TSHR P16473 1/20 0.32
TP53 P04637 1/20 0.31
ABL1 P00519 1/20 0.31
BCR P11274 1/20 0.31
OGA O60502 1/20 0.31
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3652463 0.93 ALDH1A1 (0.33) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT
SCHEMBL3017349 0.92 ALDH1A1 (0.37) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT
SCHEMBL3004059 0.91 MAPT (0.37) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT
SCHEMBL3014683 0.91 ALDH1A1 (0.39) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT
SCHEMBL3012567 0.90 ALDH1A1 (0.35) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT
SCHEMBL3022372 0.89 ALDH1A1 (0.36) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT
SCHEMBL3652789 0.89 THRB (0.36) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT
SCHEMBL3001244 0.89 ALDH1A1 (0.36) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT
SCHEMBL3011243 0.89 MAPT (0.41) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT
SCHEMBL3021199 0.88 ALDH1A1 (0.37) SMN1; SMN2ALDH1A1L3MBTL1MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.